GLP1R recombinant proteins and antibodies

Glucagon-like peptide-1 receptor (GLP1R), like gastric inhibitory peptide receptor (GIPR), belongs to the B1 class receptor family of G protein-coupled receptors (GPCR). GLP-1R is widely distributed in many tissues and organs such as the pancreas, stomach, duodenum, lungs, heart, kidneys and brain, but is mainly expressed in pancreatic β cells. The highest density of GLP-1r in the brain is in the nucleus tractus solitarius, the posterior region, the interpeduncular nucleus, the posterior dorsal nucleus and the ventral tegmental nucleus, the hypothalamic nucleus, the thalamic nucleus, the nucleus accumbens and the lateral septum. GLP1R can exert biological functions after being activated by binding to GLP1 and its analogs. More about the mechanism of action of GLP1R >>

According to incomplete statistics, there are currently 413 clinical drugs for GLP1R in the world, of which nearly 110 are preclinical, and a total of 154 are in the clinical stage and have been launched.

To assist in the development of GLP1R biotherapy, DIMA BIOTECH has produced GLP1R target recombinant protein antibody products and can also provide customized services for a variety of protein antibodies. In addition, for the GLP1R antibody lead molecule, DIMA BIOTECH has also prepared a GLP1R target single B cell seed bank, and lead antibody molecules can be obtained in as fast as 28 days; moreover, DIMA BIOTECH has currently screened dozens of GLP1R lead molecules, and customers can get the molecules for functional evaluation and verification the next day. Please contact us for details.